We are live on ! Find out more
IPSC icon

Century Therapeutics

63 hedge funds and large institutions have $59.6M invested in Century Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more call options, than puts

Call options by funds: $16K | Put options by funds: $1K

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

65% more capital invested

Capital invested by funds: $36.1M → $59.6M (+$23.5M)

16% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 19

15% more funds holding

Funds holding: 5563 (+8)

0.21% less ownership

Funds ownership: 30.22%30.01% (-0.21%)

Holders
63
Holders Change
+8
Holders Change %
+14.55%
% of All Funds
0.92%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
22
Reduced
19
Closed
7
Calls
$16K
Puts
$1K
Net Calls
+$15K
Net Calls Change
+$11K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$12M -$1.66M -912,078 -20%
CC
2
Casdin Capital
New York
$10.6M
BlackRock
3
BlackRock
New York
$5.04M -$139K -76,098 -5%
APM
4
Avidity Partners Management
Texas
$4.5M +$467K +256,500 +23%
DCM
5
DAFNA Capital Management
California
$4.34M
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.73M +$9.99K +5,483 +0.5%
TCM
7
Tang Capital Management
California
$3.54M +$1.94M +1,066,440 New
BBA
8
Baker Bros. Advisors
New York
$2.65M -$641K -351,880 -31%
Federated Hermes
9
Federated Hermes
Pennsylvania
$2.05M +$4.55K +2,500 +0.4%
Morgan Stanley
10
Morgan Stanley
New York
$1.86M +$429K +235,348 +73%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.56M +$6.87K +3,770 +0.8%
State Street
12
State Street
Massachusetts
$1.49M +$3.5K +1,920 +0.4%
Northern Trust
13
Northern Trust
Illinois
$617K -$2.21K -1,215 -0.6%
Charles Schwab
14
Charles Schwab
California
$494K +$3.57K +1,960 +1%
Millennium Management
15
Millennium Management
New York
$461K +$253K +138,960 New
BCM
16
Bridgeway Capital Management
Texas
$399K -$81.8K -44,900 -27%
Renaissance Technologies
17
Renaissance Technologies
New York
$396K +$57.4K +31,500 +36%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$335K -$128K -70,256 -41%
Citadel Advisors
19
Citadel Advisors
Florida
$332K +$75.3K +41,328 +71%
NYLIM
20
New York Life Investment Management
New York
$332K -$4.91K -2,694 -3%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$301K +$25.4K +13,950 +18%
Wealth Enhancement Advisory Services
22
Wealth Enhancement Advisory Services
Minnesota
$260K +$87.6K +48,064 +159%
N
23
Nuveen
North Carolina
$199K +$1.98K +1,087 +2%
Squarepoint
24
Squarepoint
New York
$185K -$54.4K -29,883 -35%
CIC
25
Cornercap Investment Counsel
Georgia
$171K

IPSC Hedge Fund Activity: Q4 2023 in Review

63 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q4 2023, worth a combined $59.6M — up 65% from $36.1M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new IPSC positions and 7 closed out — a net gain of 8 holders — while 22 added to existing stakes and 19 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $1.94M. The largest seller was Fidelity Investments, cutting an estimated $1.66M.

  • 63 institutional investors held Century Therapeutics (IPSC) as of Q4 2023, up from 55 in Q3 2023.
  • Funds reported $59.6M of Century Therapeutics stock for Q4 2023, up 65% quarter-over-quarter.
  • 15 funds opened new Century Therapeutics positions in Q4 2023 and 7 closed out, a net change of +8 holders.
  • The largest Century Therapeutics buyer in Q4 2023 was Tang Capital Management, an estimated $1.94M added.
  • The largest Century Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $1.66M sold.

Based on aggregated 13F filings for Q4 2023.